Furthermore, to close the gaps in our understanding of the mechanisms involved in Aβ-lowering effects of ARBs in AD, we sought to investigate the influence of losartan on the key enzymatic components of Aβ generation (beta secretase 1, BACE1) and degradation (neprilysin, NEP). Here, BACE1 is linked to Alzheimer disease.